Watchful waiting versus active surveillance: Appropriate patient selection

Current Urology Reports

Volumn 9, Issue 3, 2008, Pages 211-216

  Dall'Era, Marc A ^b   Kane, Christopher J ^a  

^a UCSD MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; GLEASON SCORE; HEALTH STATUS; HUMAN; LABORATORY DIAGNOSIS; LIFE EXPECTANCY; MORBIDITY; PATIENT SELECTION; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SCREENING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR VOLUME;

HUMANS; MALE; PATIENT SELECTION; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS;

EID: 44449118901     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-008-0037-9     Document Type: Article

References (43)

1. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101. An important study documenting the importance of grade and age on the risk of prostate cancer mortality and documenting the relatively low risk of prostate cancer mortality for older patients with low-risk prostate cancer.
2. Johansson JE, Andren O, Andersson SO, et al.: Natural history of early, localized prostate cancer. JAMA 2004, 291:2713-2719.
3. Yatani R, Chigusa I, Akazaki K, et al.: Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982, 29:611-616.
4. Rullis I, Shaeffer JA, Lilien OM: Incidence of prostatic carcinoma in the elderly. Urology 1975, 6:295-297.
5. Cooperberg MR, Lubeck DP, Meng MV, et al.: The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004, 22:2141-2149.
6. Litwin MS, Gore JL, Kwan L, et al.: Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007, 109:2239-2247.
7. Draisma G, Boer R, Otto SJ, et al.: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95:868-878.
8. Bill-Axelson A, Holmberg L, Ruutu M, et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977-1984. A very important, prospective, randomized study of surgery versus watchful waiting that documents the survival advantage of surgery.
9. Wong YN, Mitra N, Hudes G, et al.: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683-2693.
10. Tward JD, Lee CM, Pappas LM, et al.: Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer 2006, 107:2392-2400.
11. Walz J, Gallina A, Perrotte P, et al.: Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 2007, 100:1254-1258.
12. Social Security Online: Actuarial publications. Accessible at http://www.ssa.gov/OACT/pubs.html. Accessed February 2008.
13. National Center for Health Statistics: Life tables. Accessible at http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/lftbls.htm. Accessed February 2008.
14. Walz J, Gallina A, Saad F, et al.: A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007, 25:3576-3581.
15. Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994, 271:368-374.
16. Greene KL, Elkin EP, Karapetian A, et al.: Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE. J Urol 2006, 175:125-129; discussion 129.
17. Roemeling S, Roobol MJ, Postma R, et al.: Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 2006, 50:475-482.
18. Carter HB, Walsh PC, Landis P, Epstein JI: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002, 167:1231-1234. An important summary of one of the largest active surveillance cohorts in the literature.
19. Venkitaraman R, Norman A, Woode-Amissah R, et al.: Prostate-specific antigen velocity in untreated, localized prostate cancer. BJU Int 2008, 101:161-164.
20. Partin AW, Mangold LA, Lamm DM, et al.: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001, 58:843-848.
21. D'Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
22. Kattan MW, Eastham JA, Stapleton AM, et al.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766-771.
23. Cooperberg MR, Pasta DJ, Elkin EP, et al.: The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005, 173:1938-1942.
24. Kattan MW, Eastham JA, Wheeler TM, et al.: Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003, 170:1792-1797.
25. Roemeling S, Roobol MJ, Kattan MW, et al.: Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer 2007, 110:2218-2221.
26. Steyerberg EW, Roobol MJ, Kattan MW, et al.: Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007, 177:107-112; discussion 112.
27. Klotz L: Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006, 24:46-50. An excellent summary of the rationale and outcomes related to active surveillance.
28. Freedland SJ, Kane CJ, Amling CL, et al.: Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 2007, 69:495-499.
29. Emiliozzi P, Maymone S, Paterno A, et al.: Increased accuracy of biopsy Gleason score obtained by extended needle biopsy. J Urol 2004, 172:2224-2226.
30. Epstein JI, Walsh PC, Sauvageot J, Carter HB: Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997, 158:1886-1890.
31. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE: A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 1998, 159:920-924.
32. Dall'Era MA, Kane CJ, Meng MV, et al.: Pathologic outcomes for men on active surveillance who undergo radical prostatectomy do not differ from men undergoing immediate treatment. J Urol 2007, 177:203. This study documents the pathologic outcomes for a small cohort of men undergoing radical prostatectomy after an interval of active surveillance.
33. Wilt TJ, Brawer MK: The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Williston Park) 1997, 11:1133-1139; discussion 1139-1140, 1143.
34. Latini DM, Hart SL, Knight SJ, et al.: The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 2007, 178:826-831; discussion 831-822.
35. Bailey DE, Mishel MH, Belyea M, et al.: Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs 2004, 27:339-346.
36. Loblaw DA, Choo R, Zhang L, et al.: Updated follow-up of active surveillance with selected delayed intervention for localized prostate cancer. Presented at the 2nd Annual Multidiseiplinary Prostate Cancer Symposium (abstract 37). San Francisco, CA; February 24-26, 2006. A nice update of the use of PSA velocity and other clinical parameters to follow patients on active surveillance.
37. Kakehi Y, Kamoto T, Ogawa O, et al.: Prospective evaluation of a "watchful waiting" program using initial pathology criteria and PSA-doubling time monitoring for patients with stage T1c prostate cancer. J Clin Oncol 2006, 24:18S.
38. Hardie C, Parker C, Norman A, et al.: Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005, 95:956-960.
39. Carter HB, Kettermann A, Warlick C, et al.: Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007, 178:2359-2364; discussion 2364-2355.
40. Dall'Era MA, Kane CJ, Konety BR, et al.: Baseline characteristics and predictors of progression in an active surveillance cohort: the UCSF experience. J Urol 2007, 177:205.
41. Mohler JL, Williams BT, Freeman JA: Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World J Urol 1997, 15:364-368.
42. Soloway MS, Soloway CT, Williams S, et al.: Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008, 101:165-169.
43. Patel MI, DeConcini DT, Lopez-Corona E, et al.: An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004, 171:1520-1524.